Overview

Overview

Gmax Biopharm LLC. is a clinical stage biopharmaceutical company focusing on therapeutic antibody development targeting G protein-coupled receptors (GPCRs), to address the unmet medical needs in cardiovascular diseases, metabolic disorders and cancer. Founded in 2010, Gmax has attracted a talent pool of 60 people, with 15 PhDs and MDs, averaging 20 years of extensive biopharmaceutical industry experiences in multinational companies like Amgen, BMS and Genentech. Gmax has established a proprietary world-class antibody discovery platform for GPCRs. Leveraging this platform, Gmax has built up a pipeline with 9 MAbs targeting 7 different GPCRs for the treatment of diabetes, obesity, PAH, NASH and heart failure. Leveraging the expertise from the GPCR Mab platform, Gmax has also established a unique bispecific antibody platform, Bi-Body. Designed with modular structure, Bi-Body has realized the flexibility of constructing bispecific antibodies: targeting two or more biological pathways simultaneously; engaging T cells to various tumor types. Preliminary data has demonstrated that Bi-Body is superior to the BiTE® and CAR-T platforms in stability, PK, immunogenicity and manufacture. Several Bi-Bodies for esophageal cancer and nasopharyngeal cancer are under development.